ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

ACCESS ALL DATA
CHEMISTRY
Discover Molecule Insights

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0PROSPECTS

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

API REF. PRICE (USD/KG)

$ 0

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Regulatory FDF Prices

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

API

FDF

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 2569008-99-5, Prifetrastat, Pf-07248144, Prifetrastat (usan), Prifetrastat [usan], Prifetrastat [inn]

Molecular Formula

C₁₉H₁₈N₄O₅S

Molecular Weight

414.4 g/mol

InChI Key

RCBWSTJGOASLEO-UHFFFAOYSA-N

FDA UNII

GN6DU4ZE30

Prifetrastat is an inhibitor of MYST histone acetyltransferase (HAT) KAT6, with potential antineoplastic activity. Upon administration, prifetrastat targets and binds to KAT6, and inhibits the acetylation of histones and other nonhistone substrates. This may disrupt gene expression and inhibit the proliferation of tumors that overexpress KAT6. KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), commonly amplified genes in solid tumors, play key roles in cell cycle regulation and in tumorigenesis.

1 2D Structure

Kat6-IN-1

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-methoxy-N-[4-methoxy-6-(pyrazol-1-ylmethyl)-1,2-benzoxazol-3-yl]benzenesulfonamide

2.1.2 InChI

InChI=1S/C19H18N4O5S/c1-26-14-6-3-4-7-17(14)29(24,25)22-19-18-15(27-2)10-13(11-16(18)28-21-19)12-23-9-5-8-20-23/h3-11H,12H2,1-2H3,(H,21,22)

2.1.3 InChI Key

RCBWSTJGOASLEO-UHFFFAOYSA-N

2.2 Other Identifiers

2.2.1 UNII

GN6DU4ZE30

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 2569008-99-5

2. Prifetrastat

3. Pf-07248144

4. Prifetrastat (usan)

5. Prifetrastat [usan]

6. Prifetrastat [inn]

7. Gn6du4ze30

8. Orb1982278

9. Chembl6068620

10. Schembl22802427

11. Schembl29490368

12. Gtpl14088

13. Bdbm730788

14. Ex-a9009

15. 2-methoxy-n-[4-methoxy-6-(pyrazol-1-ylmethyl)-1,2-benzoxazol-3-yl]benzenesulfonamide

16. Example 34 [wo2020254946]

17. Hy-153444

18. Cs-0775007

19. Pf07248144

20. D12983

21. H41429

22. Us20250122182, Example 45, Wo2020/254946

23. 2-methoxy-n-[4-methoxy-6-(1h-pyrazol-1-ylmethyl)-1,2-benzisoxazol-3-yl]benzenesulfonamide

24. N-(6-((1h-pyrazol-1-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2-methoxybenzenesulfonamide

25. 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide

26. Benzenesulfonamide, 2-methoxy-n-[4-methoxy-6-(1h-pyrazol-1-ylmethyl)-1,2-benzisoxazol-3-yl]-

2.4 Create Date

2021-01-30

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₁₈N₄O₅S
Molecular Weight	414.4 g/mol
XLogP3	2.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	7
Exact Mass	Da
Monoisotopic Mass	Da
Topological Polar Surface Area	117
Heavy Atom Count	29
Formal Charge	0
Complexity	645
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Find Kat6-IN-1 manufacturers, exporters & distributors on PharmaCompass

Kat6-IN-1

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

FINISHED DOSAGE FORMULATIONS

0PROSPECTS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

API REF. PRICE (USD/KG)

$ 0

GLOBAL SALES INFORMATION

MARKET PLACE

DIGITAL CONTENT

What are you looking for?